Klein R G, Mannuzza S
New York State Psychiatric Institute, NY 10032.
Arch Gen Psychiatry. 1988 Dec;45(12):1131-4. doi: 10.1001/archpsyc.1988.01800360079012.
The height of young adults who were treated with methylphenidate hydrochloride in childhood because of hyperactivity (average daily dose, 45 mg; duration of treatment, six months to five years) was studied. There was no significant difference in height between the treated patients (n = 61) and controls (n = 99); both groups were at the national US norm in stature. The findings indicated that methylphenidate therapy does not compromise final height, even when it has an adverse impact on children's growth rate during the active treatment phase. A compensatory growth rate, or growth rebound, appears to occur following discontinuation of stimulant therapy.
对童年期因多动症接受盐酸哌甲酯治疗（平均日剂量45毫克；治疗持续时间为6个月至5年）的青少年的身高进行了研究。接受治疗的患者（n = 61）与对照组（n = 99）之间的身高无显著差异；两组身高均处于美国全国标准范围内。研究结果表明，即使哌甲酯治疗在积极治疗阶段对儿童生长速率有不利影响，但它不会影响最终身高。在停用兴奋剂治疗后，似乎会出现补偿性生长速率，即生长反弹。
